Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
Prostate Cancer
About this trial
This is an interventional treatment trial for Prostate Cancer focused on measuring prostate cancer, Luteinizing Hormone Releasing Hormone, LHRH
Eligibility Criteria
Inclusion Criteria: Prostate cancer treated with some form of androgen deprivation therapy for at least one month. This includes either surgical (bilateral orchidectomy) or medical (LHRH agonist, pure or steroidal antiandrogen or combined) castration; Greater than seven vasomotor episodes per week; Significantly bothersome symptoms associated with these vasomotor episodes, which produce a desire in the patient to seek treatment to reduce both their incidence and severity; Documented informed consent to participate in the trial. Exclusion Criteria: Enrolment in any other clinical trial or study protocol; Presence of pain due to prostate cancer; Life expectancy less than three months; Any severe concomitant condition that would make it undesirable, in the clinician's opinion, or the subject to participate in the trial or would jeopardize compliance with the trial protocol; Concomitant anticoagulation therapy or history of bleeding disorder or blood dyscrasia; Known hypersensitivity to Dong Quai.
Sites / Locations
- Urology Clinic & Prostate Centre, St. Joseph's Hospital, St. Joseph's Health Care London
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
1
2
Angelica Sinensis
placebo